Pengjun Zhang Selected Research

Neoplasms (Cancer)

4/2024	Nanoassembly-Mediated Exendin-4 Derivatives to Decrease Renal Retention.
12/2023	PET/NIR Fluorescence Bimodal Imaging for Targeted Tumor Detection.
1/2022	177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians.
1/2022	Detection of Bone Metastases by 68Ga-DOTA-SSAs and 18F-FDG PET/CT: A Two-Center Head-to-Head Study of Gastroenteropancreatic Neuroendocrine Neoplasms.
1/2022	Dosimetry of 177Lu-DOTATOC first circle treatment in patients with advanced metastatic neuroendocrine tumors: A pilot study in China.
1/2022	68Ga-DOTA-NT-20.3 Neurotensin Receptor 1 PET Imaging as a Surrogate for Neuroendocrine Differentiation of Prostate Cancer.
7/2019	[68Ga]Ga-NOTA-MAL-Cys39-exendin-4, a potential GLP-1R targeted PET tracer for the detection of insulinoma.
1/2019	[Theranostics of osteosarcoma and lung metastasis with new integrin α vβ 3 receptor targeted radiotracers].
1/2018	Serum exosomal microRNAs combined with alpha-fetoprotein as diagnostic markers of hepatocellular carcinoma.
2/2016	Target hepatic artery regional chemotherapy and bevacizumab perfusion in liver metastatic colorectal cancer after failure of first-line or second-line systemic chemotherapy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pengjun Zhang Research Topics

Disease

16	Neoplasms (Cancer) 04/2024 - 07/2013
5	Neoplasm Metastasis (Metastasis) 01/2022 - 02/2016
4	Hepatocellular Carcinoma (Hepatoma) 01/2018 - 03/2011
4	Colorectal Neoplasms (Colorectal Cancer) 02/2017 - 01/2011
3	Prostatic Neoplasms (Prostate Cancer) 09/2022 - 01/2022
2	Insulinoma 04/2024 - 07/2019
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2022 - 07/2019
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2020 - 09/2019
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2018 - 03/2011
2	Iron Overload 12/2016 - 01/2016
2	Stomach Neoplasms (Stomach Cancer) 02/2016 - 03/2011
2	Pathologic Processes 01/2016 - 05/2015
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 09/2014 - 09/2013
2	Sepsis (Septicemia) 02/2012 - 01/2012
1	Paraganglioma (Paragangliomas) 04/2024
1	Pheochromocytoma 04/2024
1	Colonic Neoplasms (Colon Cancer) 12/2023
1	Weight Gain 10/2023
1	Skeletal Abnormalities Mandibular Hypoplasia Auditory Canal Atresia Short Stature 12/2022
1	Lymphadenopathy 01/2022
1	Osteolysis 01/2022
1	COVID-19 01/2021
1	Inflammation (Inflammations) 01/2020
1	Osteoarthritis 01/2020
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 09/2019
1	Large Cell Carcinoma 09/2019
1	Adenocarcinoma of Lung 09/2019
1	Osteosarcoma (Osteogenic Sarcoma) 01/2019
1	Graft vs Host Disease (Graft-Versus-Host Disease) 08/2017
1	Liver Neoplasms (Liver Cancer) 01/2016
1	Heart Failure 01/2016
1	Ovarian Epithelial Carcinoma 12/2015
1	Unstable Angina 05/2015
1	Pancreatic Neoplasms (Pancreatic Cancer) 06/2014
1	Infections 07/2013
1	Systemic Inflammatory Response Syndrome (Sepsis Syndrome) 02/2012

Drug/Important Bio-Agent (IBA)

8	Biomarkers (Surrogate Marker)IBA 08/2017 - 01/2012
7	MicroRNAs (MicroRNA)IBA 01/2020 - 03/2011
4	AntigensIBA 09/2022 - 09/2013
2	Exenatide (Byetta)FDA Link 04/2024 - 07/2019
2	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 12/2023 - 01/2022
2	MetalsIBA 12/2022 - 01/2016
2	gallium 68 PSMA-11IBA 09/2022 - 01/2022
2	Therapeutic UsesIBA 01/2020 - 01/2019
2	IronIBA 12/2016 - 01/2016
2	Melanins (Melanin)IBA 12/2016 - 01/2016
2	Proteins (Proteins, Gene)FDA Link 12/2015 - 01/2015
1	anlotinibIBA 04/2024
1	AnionsIBA 12/2023
1	Anti-Bacterial Agents (Antibiotics)IBA 10/2023
1	ElectrolytesIBA 12/2022
1	ZincIBA 12/2022
1	NeurotensinIBA 01/2022
1	PSMA I&TIBA 01/2022
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2022
1	Neurotensin Receptors (Neurotensin Receptor)IBA 01/2022
1	Somatostatin Receptors (Somatostatin Receptor)IBA 01/2022
1	DOTA(0)-Tyr(3)- 177Lu-octreotideIBA 01/2022
1	Immunoglobulin M (IgM)IBA 01/2021
1	Nucleic AcidsIBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2021
1	Competitive Endogenous RNAIBA 01/2020
1	Long Noncoding RNAIBA 01/2020
1	Keratin-19 (Keratin 19)IBA 09/2019
1	Glucagon-Like Peptide-1 ReceptorIBA 07/2019
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 07/2019
1	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 07/2019
1	IntegrinsIBA 01/2019
1	Dihydrotachysterol (AT 10)IBA 01/2019
1	68Ga-NODAGA-RGDIBA 01/2019
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2018
1	CytokinesIBA 08/2017
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 02/2017
1	Bevacizumab (Avastin)FDA Link 02/2016
1	N 30IBA 02/2016
1	Peptides (Polypeptides)IBA 01/2016
1	Chelating AgentsIBA 01/2016
1	FSH Receptors (FSH Receptor)IBA 01/2016
1	IonsIBA 01/2016
1	Tumor Biomarkers (Tumor Markers)IBA 01/2016
1	pro-brain natriuretic peptide (1-76)IBA 01/2016
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 01/2016
1	Natriuretic PeptidesIBA 01/2016
1	AntioxidantsIBA 01/2015
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2015
1	Uric Acid (Urate)IBA 01/2015
1	RNA (Ribonucleic Acid)IBA 09/2014
1	CarbohydratesIBA 09/2013
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2013
1	squamous cell carcinoma-related antigenIBA 09/2013
1	Cell-Free Nucleic AcidsIBA 07/2013
1	hydrogen sulfite (bisulfite)IBA 07/2013
1	DNA (Deoxyribonucleic Acid)IBA 07/2013

Therapy/Procedure

5	Therapeutics 01/2022 - 09/2013
2	Drug Therapy (Chemotherapy) 02/2017 - 02/2016
1	Electrodes (Electrode) 12/2022
1	Castration 01/2022
1	Radiotherapy 01/2019
1	Precision Medicine 01/2019
1	Hematopoietic Stem Cell Transplantation 08/2017